Cipla Ltd.

Cipla has launched antibody detection kits for COVID-19 in India under the brand name 'ELIFast' in partnership with KARWA, under the technology transfer from the Indian Council of Medical Research (ICMR). As part of the collaborative effort, the company will be responsible for the marketing and distribution of the SARS CoV-2-IgG antibody detection ELISA that will be manufactured by KARWA.

ICMR has provided the requisite technological know-how and process for developing the test kits to the approved manufacturers. The company's distribution network will help in ensuring the seamless supply of kits across the country. Supply will be undertaken through the channels approved by ICMR to ensure equitable access.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.